Medical Laboratory Sciences Program, Division of Health Professions, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
Center for Infectious Diseases Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
J Immunol Res. 2023 May 16;2023:7258585. doi: 10.1155/2023/7258585. eCollection 2023.
Since its emergence, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a public health threat worldwide. While the majority of patients recover in 3-4 weeks, complications in severely ill patients, including acute respiratory distress syndrome, cardiac injury, thrombosis, and sepsis, can lead to death. Several biomarkers, in addition to cytokine release syndrome (CRS), have been associated with severe and fatal outcomes in coronavirus disease 2019 (COVID-19) patients. The aim of this study is to assess clinical characteristics and cytokines profiles in hospitalized COVID-19 patients in Lebanon. A total of 51 hospitalized COVID-19 patients were recruited between February 2021 and May 2022. Clinical data and sera were collected at two time points: at hospital presentation (T0) and last collected results during hospitalization (T1). Our results showed that 49% of participants were >60 years with males accounting for the majority (72.5%). Hypertension, followed by diabetes and dyslipidemia, were the most frequent comorbid conditions among study participants accounting for 56.9% and 31.4%, respectively. Chronic obstructive pulmonary disease (COPD) was the only significantly different comorbid condition between intensive care unit (ICU) and non-ICU patients. Our results also showed that the median level of D-dimer was significantly elevated among patients in ICU and those who died compared to non-ICU patients and those who survived. Moreover, C-reactive protein (CRP) levels were significantly higher at T0 compared to T1 in ICU and non-ICU patients. The median level of IL-12p70 was significantly higher in patients >60 years compared to those ≤60 years ( = 0.0209). Our data are in agreement with previous reports suggesting the importance of IL-6, CRP, and IL-12p70 in the assessment of risk of severe disease and mortality.
自出现以来,严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)仍然是全球公共卫生威胁。虽然大多数患者在 3-4 周内康复,但重症患者的并发症,包括急性呼吸窘迫综合征、心脏损伤、血栓形成和败血症,可能导致死亡。除细胞因子释放综合征(CRS)外,几种生物标志物与 2019 年冠状病毒病(COVID-19)患者的严重和致命结局相关。本研究旨在评估黎巴嫩住院 COVID-19 患者的临床特征和细胞因子谱。共招募了 51 名住院 COVID-19 患者,时间为 2021 年 2 月至 2022 年 5 月。在两个时间点收集临床数据和血清:入院时(T0)和住院期间的最后一次采集结果(T1)。我们的结果显示,49%的参与者年龄>60 岁,男性占多数(72.5%)。高血压,其次是糖尿病和血脂异常,是研究参与者中最常见的合并症,分别占 56.9%和 31.4%。慢性阻塞性肺疾病(COPD)是 ICU 和非 ICU 患者之间唯一显著不同的合并症。我们的结果还表明,ICU 患者和死亡患者的 D-二聚体中位数明显高于非 ICU 患者和存活患者。此外,与 T1 相比,ICU 和非 ICU 患者的 C 反应蛋白(CRP)水平在 T0 显著升高。60 岁以上患者的 IL-12p70 中位数明显高于 60 岁以下患者(=0.0209)。我们的数据与之前的报告一致,表明 IL-6、CRP 和 IL-12p70 在评估严重疾病和死亡率风险方面的重要性。